Matches in Wikidata for { <http://www.wikidata.org/entity/Q86241648> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q86241648 description "assaig clínic" @default.
- Q86241648 description "clinical trial" @default.
- Q86241648 description "clinical trial" @default.
- Q86241648 description "clinical trial" @default.
- Q86241648 description "clinical trial" @default.
- Q86241648 description "ensaio clínico" @default.
- Q86241648 description "ensayo clínico" @default.
- Q86241648 description "ensayu clínicu" @default.
- Q86241648 description "essai clinique" @default.
- Q86241648 description "klinisch onderzoek" @default.
- Q86241648 description "клінічне випробування" @default.
- Q86241648 name "A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241648 name "A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241648 type Item @default.
- Q86241648 label "A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241648 label "A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241648 prefLabel "A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241648 prefLabel "A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241648 P1050 Q86241648-58AF4574-BCE5-4552-BE36-5BDD79C091BA @default.
- Q86241648 P1050 Q86241648-7D1C9A25-9CA8-45A6-AFB2-86EAD8370FBD @default.
- Q86241648 P1132 Q86241648-778591AB-FBC8-47D4-9D9B-F14E425B628E @default.
- Q86241648 P1476 Q86241648-8E8EAA43-EE55-43E7-8717-ACDA22FAEFA7 @default.
- Q86241648 P1813 Q86241648-4329025C-928D-48AA-832B-CA0E63743B37 @default.
- Q86241648 P2899 Q86241648-C4D6663D-7B67-4C71-A85E-A19FA0EC7D12 @default.
- Q86241648 P3098 Q86241648-98E8D8C7-1E8F-4306-8774-50C0A84A9996 @default.
- Q86241648 P31 Q86241648-D0390585-352A-41E1-ADF8-5D885C8BB0E1 @default.
- Q86241648 P580 Q86241648-54E935A8-23C3-4DFF-A827-99D992A72EFD @default.
- Q86241648 P582 Q86241648-85ECC0D3-0B3A-4410-9F82-161C44E54BA5 @default.
- Q86241648 P6099 Q86241648-591616CA-7B57-4D3F-92D1-D526B3AC4CE8 @default.
- Q86241648 P8363 Q86241648-84201EBA-8CF7-4F99-B15E-9B5D63A72356 @default.
- Q86241648 P921 Q86241648-7726011F-2D1B-4FBF-AC06-93694806DEAE @default.
- Q86241648 P1050 Q2298953 @default.
- Q86241648 P1050 Q341999 @default.
- Q86241648 P1132 "+490" @default.
- Q86241648 P1476 "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241648 P1813 "BE HEARD II" @default.
- Q86241648 P2899 "+18" @default.
- Q86241648 P3098 "NCT04242498" @default.
- Q86241648 P31 Q30612 @default.
- Q86241648 P580 "2020-02-01T00:00:00Z" @default.
- Q86241648 P582 "2022-02-28T00:00:00Z" @default.
- Q86241648 P6099 Q42824827 @default.
- Q86241648 P8363 Q78089383 @default.
- Q86241648 P921 Q341999 @default.